NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

TA323; Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia

Consultees Commentators (no right to submit or	
Consultees	appeal)
Manufacturers/sponsors	General
Amgen (darbepoetin alfa)	Allied Health Professionals Federation
 Hospira (epoetin zeta) 	Board of Community Health Councils in
 Janssen-Cilag (epoetin alfa) 	Wales
 Roche Products (epoetin beta) 	British National Formulary
 Sandoz (epoetin alfa) 	Care Quality Commission
 Teva UK (epoetin theta) 	Department of Health, Social Services
	and Public Safety for Northern Ireland
Patient/carer groups	Healthcare Improvement Scotland
Aplastic Anaemia Trust	Medicines and Healthcare products
Black Health Agency	Regulatory Agency
British Lung Foundation	National Association of Primary Care
Cancer Black Care	NHS Alliance
Cancer Equality	 NHS Blood and Transplant
Cancer52	 NHS Commercial Medicines Unit
HAWC	NHS Confederation
Helen Rollason Cancer Charity	 Public Health Wales NHS Trust
Independent Cancer Patients Voice	Scottish Medicines Consortium
 Macmillan Cancer Support 	
Maggie's Centres	Comparator manufacturers
Marie Curie	None
Muslim Council of Britain	
Roy Castle Lung Cancer Foundation	Relevant research groups
 South Asian Health Foundation 	Cochrane Haematological Malignancies
 Specialised Healthcare Alliance 	 Group Elimination of Leukaemia Fund
Tenovus	
	 Health Research Authority Institute of Cancer Research
Professional groups	
Association of Cancer Physicians	 Leukaemia Busters MRC Clinical Trials Unit
British Blood Transfusion Society	National Concern Dessarsh Institute
British Committee for Standards in	 National Cancer Research Institute National Cancer Research Network
Haematology	 National Institute for Health Research
British Geriatrics Society Driviah Development Consistent	 Research Institute for the Care of Older
British Psychosocial Oncology Society	People
British Society for Haematology	
Cancer Research UK Devel Callege of Concerel Dractitioners	
Royal College of General Practitioners	

Matrix of consultees and commentators

National Institute for Health and Care Excellence TA323; Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia

٠	Royal College of Nursing
•	Royal College of Pathologists
٠	Royal College of Physicians
•	Royal Pharmaceutical Society
•	Royal Society of Medicine
•	United Kingdom Chronic Lymphocytic
	Leukaemia Forum
٠	United Kingdom Clinical Pharmacy
	Association
•	United Kingdom Oncology Nursing
	Society
<u>Ot</u>	<u>hers</u>
٠	Department of Health
٠	NHS Darlington CCG
٠	NHS Harrogate and Rural District
	CCG
٠	NHS England
•	Welsh Assembly Government

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.